Jonah Sacha did not think it would work. Each of the three therapies his team combined had already been tried against HIV on its own, and each had failed to permanently clear the virus. Stacking them together seemed unlikely to change that arithmetic.
It did. In a study published in Nature Microbiology on Aug. 10, researchers led by Oregon Health & Science University reported that eight infant macaques given a combination regimen starting 72 hours after infection showed no detectable virus anywhere investigators looked, roughly a year after treatment was stopped.
"There was no reason to think this would completely clear the virus," said Sacha, professor and chief of pathobiology and immunology at OHSU's Oregon National Primate Research Center. Nancy Haigwood, the virologist and immunologist who suggested the combination, was blunter: "We were astounded and overjoyed, actually."
Three Drugs Doing Three Different Jobs
The animals were roughly a month old and infected orally with SHIVSF162P3, a hybrid simian-human immunodeficiency virus that is aggressive enough in infant macaques to model perinatal HIV. Treatment began 72 hours after exposure, once the virus was already measurable in the blood.
The regimen had three components. Daily antiretroviral therapy, a subcutaneous combination of tenofovir, emtricitabine, and dolutegravir, suppressed replication for 27 weeks. A single subcutaneous bolus of two broadly neutralizing antibodies, PGT121 and VRC07-523LS, at 20 mg/kg each, mopped up circulating virus. And roughly eight weeks of leronlimab, an experimental monoclonal antibody, blocked the CCR5 receptor that most transmitted HIV uses to enter immune cells.
Haigwood describes the sequence as turning off a faucet, mopping the floor, then sealing the room.
The design was unusually systematic: 55 infant macaques were assigned to seven treatment approaches, including untreated controls and animals given one or two components rather than all three. None of the partial regimens worked reliably. Antibodies alone at 72 hours blunted early viremia but rebounded in all six animals. Leronlimab alone reduced the reservoir without eliminating it. Antibodies plus antiretrovirals still rebounded.
Why the First Three Days Appear to Matter So Much
The finding that will interest cure researchers is not that a combination worked. It is where in the infection timeline it worked.
HIV seeds a latent reservoir within days, which is why treatment is lifelong. This study suggests that during a narrow early window, the reservoir has not yet been securely established.
"For reasons we don't understand, HIV really wants to use CCR5 receptors to infect cells," Sacha said. Blocking that access, in his framing, kept fuel away from the fire.
The team had previously shown that a single antibody cocktail administered 30 hours after exposure could clear SHIV in infant macaques (Nature Communications). The window closed fast: at 48 hours, the same bolus cleared five of six animals, and at 72 hours, it failed. Adding two more mechanisms reopened it.
Researchers did not settle for absent viral loads. At 56 weeks, they searched for HIV-specific CD8 T cells and antibodies against the viral envelope and found neither in any of the eight animals, indicating that the animals had never mounted an immune response to a persistent infection. At 61 weeks, they completely depleted CD8 T cells, a stress test that caused the virus to reappear in controls and in the antibody-plus-antiretroviral animals. In the triple therapy group, nothing came back. At necropsy, an assay designed to detect intact and defective proviruses in CD4 T cells found neither.
"How far can you go after infection and still purge the virus?" Sacha asked, framing the open question the group now wants to answer.
What This Does Not Mean for Babies with HIV
This was a nonhuman primate study in eight treated animals. It does not establish that the approach cures HIV in human newborns, and no human has been treated this way.
Two of the three components are not approved for this use. Antiretroviral therapy is standard care, but broadly neutralizing antibodies and leronlimab are still in separate clinical trials, including a randomized leronlimab trial in multidrug-resistant HIV. Any pediatric application would require new trials.
The authors flag their own limits. Deeper sampling of bone marrow or the central nervous system might have found latent viruses they missed. The approach may not work against strains that enter cells through CXCR4 rather than CCR5. And whether it translates to adult infection is untested.
There is also a disclosure worth stating plainly. OHSU notes that Sacha and co-author Scott Hansen have had a significant financial interest in CytoDyn, the company that supplied clinical-grade leronlimab, and may have a commercial interest in the results. The university says it manages such relationships through its conflict of interest program.
The Practical Obstacle Nobody Has Solved
The 72-hour requirement is itself formidable. It assumes the mother's HIV status is known, that the infant is tested immediately, and that all three agents are available within three days of birth. Infants infected in the womb rather than during delivery would fall outside the window.
More than 120,000 children acquire HIV each year, and the epidemic still kills roughly 600,000 people worldwide annually. For those infants, current care means lifelong daily medication, assuming access and affordability.
The direction of travel in human medicine is at least consistent. A proof-of-concept study of neonatal antiretroviral therapy found that starting treatment within days of birth reduced the size of the HIV reservoir, which the macaque authors cite as supporting evidence.
Sacha said the work could move to trials quickly, most likely first in newly exposed adults. The research was supported by the National Institute of Child Health and Human Development and the National Institute of Allergy and Infectious Diseases, among other NIH sources.
Anyone with questions about HIV testing during pregnancy or infant prophylaxis should raise them with an obstetrician or pediatrician rather than drawing conclusions from animal research.
Key Questions Answered
What did researchers find?
A combination of antiretroviral therapy, two broadly neutralizing antibodies, and leronlimab, started 72 hours after infection, left no detectable virus in eight infant macaques.
How thoroughly did they check?
Beyond viral load, they looked for HIV-specific immune responses, depleted CD8 cells to provoke rebound, and searched tissues for intact and defective proviruses at necropsy. All came back negative.
Does this cure HIV in babies?
No. The study was conducted in macaques. No human infant has been treated with this regimen.
Why does the 72-hour window matter?
HIV seeds a latent reservoir within days. Antibodies alone worked at 30 and 48 hours but failed at 72. Adding two mechanisms extended the window.
What is leronlimab?
An experimental monoclonal antibody that blocks the CCR5 receptor HIV uses to enter immune cells. It is not FDA-approved for this purpose.
Are there conflicts of interest?
OHSU discloses that two co-authors have had a significant financial interest in CytoDyn, which supplied the leronlimab and may have a commercial interest in the results.
What are the main limitations?
Eight treated animals, no sampling of bone marrow or the brain, and a mechanism that may not work against HIV strains using the CXCR4 receptor.
